Abstract
Objective To investigate the expression of mutant p53, Ki-67, ER and PR in uterine endometrial carcinoma and uterine serous carcinoma, and explore their significance in differential diagnosis. Methods The samples including 37 cases of uterine endometrial carcinoma and 37 cases of uterine serous carcinoma were analyzed. The expression of mutant p53, Ki-67, estrogen receptor and progesterone receptor were performed by using the immunocytochemical (IHC) EnVision system. Data were analyzed with SPSS 11.5 statistic software. Results The positive rate of mutant p53 in uterine endometrial carcinoma was statistically lower than that in uterine serous carcinoma [21.62 % (8/37) vs 64.86 % (24/37) (P<0.01)]. The positive rate of Ki-67 in uterine endometrial carcinoma was statistically lower than that in uterine serous carcinoma [37.84 % (14/37) vs 70.27 % (24/37) (P<0.01)]. The positive rate of estrogen receptor in uterine endometrial carcinoma was statistically higher than that in uterine serous carcinoma [78.38 % (29/37) vs 32.43 % (12/37) (P<0.01)]. The positive rate of progesterone receptor in uterine endometrial carcinoma was statistically higher than that in uterine serous carcinoma [75.67 % (28/37) vs 29.73 % (11/37) (P<0.01)]. Conclusions The expression of mutant p53 and Ki-67 are higher in uterine serous carcinoma. The expression of estrogen receptor and progesterone receptor are higher in uterine endometrial carcinoma. Combined detection of mutant p53, Ki-67, ER and PR has important significance in screening and preventing uterine endometrial carcinoma and uterine serous carcinoma. Key words: Endometrioid carcinoma; Uterine serous carcinoma; p53; Ki-67; ER; PR; Differential diagnosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
